Literature DB >> 20132888

Taurine deficiency damages photoreceptors and retinal ganglion cells in vigabatrin-treated neonatal rats.

Firas Jammoul1, Julie Dégardin, Dorothée Pain, Pauline Gondouin, Manuel Simonutti, Elisabeth Dubus, Romain Caplette, Stéphane Fouquet, Cheryl M Craft, José A Sahel, Serge Picaud.   

Abstract

The anti-epileptic drug vigabatrin induces an irreversible constriction of the visual field, but is still widely used to treat infantile spasms and some forms of epilepsy. We recently reported that vigabatrin-induced cone damage is due to a taurine deficiency. However, optic atrophy and thus retinal ganglion cell degeneration was also reported in children treated for infantile spasms. We here show in neonatal rats treated from postnatal days 4 to 29 that the vigabatrin treatment triggers not only cone photoreceptor damage, disorganisation of the photoreceptor layer and gliosis but also retinal ganglion cell loss. Furthermore, we demonstrate in these neonatal rats that taurine supplementation partially prevents these retinal lesions and in particular the retinal ganglion cell loss. These results provide the first evidence of retinal ganglion cell neuroprotection by taurine. They further confirm that taurine supplementation should be administered with the vigabatrin treatment for infantile spasms or epilepsy. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20132888      PMCID: PMC2864319          DOI: 10.1016/j.mcn.2010.01.008

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  39 in total

1.  Vigabatrin: longterm follow-up of electrophysiology and visual field examinations.

Authors:  Peter Hardus; Willem Verduin; Tos Berendschot; Gina Postma; Jan Stilma; Cees van Veelen
Journal:  Acta Ophthalmol Scand       Date:  2003-10

2.  Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings.

Authors:  N R Miller; M A Johnson; S R Paul; C A Girkin; J D Perry; M Endres; G L Krauss
Journal:  Neurology       Date:  1999-12-10       Impact factor: 9.910

3.  Mouse cone arrestin expression pattern: light induced translocation in cone photoreceptors.

Authors:  Xuemei Zhu; Aimin Li; Bruce Brown; Ellen R Weiss; Shoji Osawa; Cheryl M Craft
Journal:  Mol Vis       Date:  2002-12-11       Impact factor: 2.367

4.  Vigabatrin effect on inner retinal function.

Authors:  S G Coupland; D H Zackon; B C Leonard; T M Ross
Journal:  Ophthalmology       Date:  2001-08       Impact factor: 12.079

5.  Visual field and electrophysiological abnormalities due to vigabatrin.

Authors:  Kors van der Torren; Hellen S Graniewski-Wijnands; B C P Polak
Journal:  Doc Ophthalmol       Date:  2002-03       Impact factor: 2.379

6.  The effects of vigabatrin on electrophysiology and visual fields in epileptics: a controlled study with a discussion of possible mechanisms.

Authors:  I F Comaish; C Gorman; G M Brimlow; C Barber; G M Orr; N R Galloway
Journal:  Doc Ophthalmol       Date:  2002-03       Impact factor: 2.379

7.  The Hospital for Sick Children, Toronto, Longitudinal ERG study of children on vigabatrin.

Authors:  Carol A Westall; William J Logan; Kim Smith; J Raymond Buncic; Carole M Panton; Mohamed Abdolell
Journal:  Doc Ophthalmol       Date:  2002-03       Impact factor: 2.379

8.  Characterization of vigabatrin-associated optic atrophy.

Authors:  Lars Frisén; Kristina Malmgren
Journal:  Acta Ophthalmol Scand       Date:  2003-10

Review 9.  Current management for epilepsy in tuberous sclerosis complex.

Authors:  Paolo Curatolo; Roberta Bombardieri; Caterina Cerminara
Journal:  Curr Opin Neurol       Date:  2006-04       Impact factor: 5.710

10.  [Vigabatrin-associated bilateral simple optic nerve atrophy with visual field constriction. A case report and a survey of the literature].

Authors:  Arne Viestenz; Anja Viestenz; C Y Mardin
Journal:  Ophthalmologe       Date:  2003-05       Impact factor: 1.059

View more
  21 in total

1.  mTOR Inhibition Mitigates Molecular and Biochemical Alterations of Vigabatrin-Induced Visual Field Toxicity in Mice.

Authors:  Kara R Vogel; Garrett R Ainslie; Michelle A Schmidt; Jonathan P Wisor; K Michael Gibson
Journal:  Pediatr Neurol       Date:  2016-10-03       Impact factor: 3.372

2.  Evaluation of inner retinal layers with optic coherence tomography in vigabatrin-exposed patients.

Authors:  Betül Tuğcu; Mesrure Köseoğlu Bitnel; Fatma Selin Kaya; Betül Tekin Güveli; Dilek Ataklı
Journal:  Neurol Sci       Date:  2017-05-16       Impact factor: 3.307

Review 3.  Recent advances in the pharmacotherapy of infantile spasms.

Authors:  Raili Riikonen
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

4.  Taurine trial in succinic semialdehyde dehydrogenase deficiency and elevated CNS GABA.

Authors:  Phillip L Pearl; John Schreiber; William H Theodore; Robert McCarter; Emily S Barrios; Joe Yu; Edythe Wiggs; Jianping He; K Michael Gibson
Journal:  Neurology       Date:  2014-02-12       Impact factor: 9.910

5.  Vigabatrin can enhance electroretinographic responses in pigmented and albino rats.

Authors:  James D Akula; Emily R Noonan; Alessia Di Nardo; Tara L Favazza; Nan Zhang; Mustafa Sahin; Ronald M Hansen; Anne B Fulton
Journal:  Doc Ophthalmol       Date:  2015-03-12       Impact factor: 2.379

6.  Clinical profile of vigabatrin as monotherapy for treatment of infantile spasms.

Authors:  Jason T Lerner; Noriko Salamon; Raman Sankar
Journal:  Neuropsychiatr Dis Treat       Date:  2010-11-08       Impact factor: 2.570

7.  Reciprocal regulation between taurine and glutamate response via Ca2+-dependent pathways in retinal third-order neurons.

Authors:  Simon Bulley; Wen Shen
Journal:  J Biomed Sci       Date:  2010-08-24       Impact factor: 8.410

Review 8.  Latest American and European updates on infantile spasms.

Authors:  Andrew L Lux
Journal:  Curr Neurol Neurosci Rep       Date:  2013-03       Impact factor: 5.081

9.  Taurine deficiency damages retinal neurones: cone photoreceptors and retinal ganglion cells.

Authors:  David Gaucher; Emilie Arnault; Zoé Husson; Nicolas Froger; Elisabeth Dubus; Pauline Gondouin; Diane Dherbécourt; Julie Degardin; Manuel Simonutti; Stéphane Fouquet; M A Benahmed; K Elbayed; Izzie-Jacques Namer; Pascale Massin; José-Alain Sahel; Serge Picaud
Journal:  Amino Acids       Date:  2012-04-04       Impact factor: 3.520

10.  Taurine provides neuroprotection against retinal ganglion cell degeneration.

Authors:  Nicolas Froger; Lucia Cadetti; Henri Lorach; Joao Martins; Alexis-Pierre Bemelmans; Elisabeth Dubus; Julie Degardin; Dorothée Pain; Valérie Forster; Laurent Chicaud; Ivana Ivkovic; Manuel Simonutti; Stéphane Fouquet; Firas Jammoul; Thierry Léveillard; Ryad Benosman; José-Alain Sahel; Serge Picaud
Journal:  PLoS One       Date:  2012-10-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.